A double blind placebo controlled parallel group mulitcentre randomised Phase III survival study comparing ZD 1839 IRESSA 250mg tablet plus Best Supportive Care versus placebo plus Best Supportive Care in patients with Advanced NSCLC who have received one or two prior chemotherapy regimens and are refractory or intolerant to their most recent regimen ZD1839IL 0709